Welcome to Seacross Pharmaceuticals Ltd.
Oncology Injectable Other Product 1 Other Product 2
Azacitidine 25 mg/mL

Therapeutic indications: 

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

• intermediate-2 and high-risk myelodysplastic syndromes (MDS) per the International Prognostic Scoring System (IPSS),

• chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,

• acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, per World Health Organisation (WHO) classification,

• AML with >30% marrow blasts per the WHO classification.

Form Powder for suspension for injection
Strength 100mg/vial
Active substance Azacitidine
Other ingredients Mannitol (E421), water for injections
© Copyright - Clinico fusce blandit sapien eu